Unicorn Techno 2025: The Market Is Giving Credit Mostly to the Cash, and the Private Portfolio Still Needs Proof

Getting To Know The Company

Unicorn Techno is not another small tech company waiting for its next product cycle. It is a public R&D partnership, effectively a listed wrapper around a portfolio of private early-stage technology companies. There is no operating revenue engine here, no recurring EBITDA layer, and no self-funding core business. At the end of 2025, what matters is mostly NIS 13.5 million of cash, NIS 30.6 million of fair-value financial assets, and a wrapper run by only 2 employees.

What is working now is not the partnership's operating model, but three other things: there is no debt, expenses came down, and the valuation line almost stopped deteriorating. Net loss narrowed to NIS 4.0 million from NIS 6.8 million in 2024, while fair-value change on the portfolio was only negative NIS 305 thousand versus negative NIS 3.8 million a year earlier. That is meaningful. After two years of sharp markdowns, stabilization itself is already an event.

But this is also where a superficial read can mislead. Year-end 2025 looks decent on the balance sheet, with equity of NIS 43.6 million against a market cap of roughly NIS 20.1 million in early April 2026. On first glance, that looks like a deep discount to NAV. On second glance, almost the entire portfolio is Level 3, which means the marks rely on models, recent funding rounds, or management estimates, and Strix alone stands at NIS 13.3 million, about 43.5% of the whole portfolio. The market is not really arguing about cash. It is arguing about how credible the private marks above cash actually are.

That is why Unicorn's active bottleneck is not debt but value accessibility. The partnership ends the year with no loans and only NIS 725 thousand of current liabilities, but also with no meaningful realizations, no distributable surplus, and negative operating cash flow of NIS 3.4 million. So the real question for 2026 is not whether Unicorn can meet a near-term maturity. The real question is whether one or more of the portfolio's valuation anchors can move to the next stage of external validation or realization, so that the stated value starts to look accessible to public unitholders as well.

That makes 2025 look like a stabilization year in accounting terms, but a proof year on the screen.

Four non-obvious findings right at the start:

• The cash balance was preserved by the market, not by the business. Cash rose slightly to NIS 13.5 million, but only after a net rights offering of NIS 7.3 million. Without that raise, cash would have fallen sharply.
• The debate is concentrated in one company. Strix accounts for roughly 43.5% of the portfolio, and its year-end mark is still based on a very material valuation dated June 30, 2025.
• The earnings improvement does not mean the wrapper became profitable. The loss narrowed mainly because fair-value marks stabilized and overhead declined, not because the partnership generated cash or exits.
• Even the investment pace was slightly higher than it looks in the cash flow. Financial assets increased by NIS 3.629 million, versus cash outflow of NIS 3.290 million, because the ActualSignal warrant exercise was booked as an investment against payables and was only paid in January 2026.

The economic map at the end of 2025 looks like this:

This chart is the core of the story. Market cap stands only modestly above cash, and far below either equity or portfolio fair value. Anyone reading that as an automatic bargain misses the real dispute: the market is not ignoring the numbers, it is discounting the speed and quality with which those numbers can turn into accessible value.

This also shows that the balance sheet grew in 2025, but almost all of that growth sits in two pockets only: cash and the investment portfolio. There is no operating asset layer providing an additional cushion. That makes the quality of every shekel inside the portfolio more important than the portfolio's absolute size.

Events And Triggers

The rights offering bought time, but also clarified the model's dependence on the market

First trigger: November 2025. Unicorn raised roughly NIS 7.509 million gross, and NIS 7.314 million net, through a rights offering. That clearly strengthens the cash position and removes immediate pressure, but it also says something uncomfortable: even after a year of smaller losses and a more stable portfolio, the wrapper still does not live off realizations. It lives off its ability to come back to the market and raise equity.

Another important event preceded the raise. In June 2025, the general meeting did not approve the extension of the management-fee arrangement between the partnership and the general partner from September 9, 2025 onward. This was not a minor detail. It is one of the main reasons general and administrative expenses fell to NIS 3.671 million from NIS 4.074 million. In other words, public unitholders blocked a cost layer, and the year-end numbers already reflect that decision.

But both sides need to be tested. On one hand, this is healthy cost discipline. On the other hand, if the wrapper needs both lower fees and fresh equity just to preserve cash, the model still has not reached the point where the portfolio funds itself through realizations or distributions.

Strix and Flow-Lit provided validation anchors, but not an exit

Second trigger: August 2025. Strix's US subsidiary signed an agreement with an American aerial-infrastructure company to supply Strix systems through the end of 2025, with consideration of USD 2.15 million in the first phase. This matters because Strix is the portfolio's main valuation anchor. When the largest company in the portfolio gets this kind of commercial signal, it becomes easier to understand why the June 2025 valuation stepped up so sharply.

Third trigger: September 2025. Flow-Lit signed an investment agreement with Dor Chemicals for USD 1 million. That matters for two reasons. First, it gives a more external anchor to the mark. Second, it is not clean. The last two tranches are contingent on receiving ATEX certification for Flow-Lit's optoelectronic technology. So there is validation here, but it is still partial and execution dependent.

That distinction is important. An external funding agreement is not the same thing as a realization. It strengthens the case that the mark is not detached from reality, but it does not generate cash for Unicorn itself and it does not remove the operating risk between a commercial milestone and accessible value.

2025 was a portfolio-building year, not a harvest year

Fourth trigger: what the partnership actually did with the money. During 2025 Unicorn entered Engini through a USD 500 thousand SAFE, made an initial USD 150 thousand investment in Inteil, then bought another USD 150 thousand of Inteil shares from existing shareholders. It also added USD 100 thousand to Supersi, USD 50 thousand to VibeZ, and exercised a warrant for ActualSignal preferred shares for USD 106 thousand.

That sequence says the partnership is still acting like a young venture-style platform building and deepening positions, not like a wrapper already harvesting results. That is not inherently bad, but it changes the lens. A partnership at this stage should be judged on the quality of its marks and on the future realization path, not merely on the existence of a diversified portfolio.

Fifth trigger: after the balance-sheet date, in February 2026, Unicorn also joined another SAFE round in LeO for USD 150 thousand. That further reinforces the sense that 2026 begins as a continuation of the build phase rather than the start of a distribution phase.

Efficiency, Profitability And Competition

The improvement in the income statement is mainly a valuation story

The comprehensive loss statement looks better in 2025, but it is important to be precise about what actually improved. Fair-value change on financial assets was only negative NIS 305 thousand, versus negative NIS 3.797 million in 2024 and negative NIS 11.259 million in 2023. That is a major easing. It means the sharp decline in portfolio values largely stopped, and the latest year no longer looked like another wave of write-downs.

But that does not mean the wrapper itself became profitable. Unicorn does not sell products and does not earn recurring management fees from third parties. When fair-value pressure eases, the loss narrows. When the mark swings positive, reported performance can improve very quickly. That is exactly what happened in the second half of 2025.

The chart shows that the story changed between 2023 and 2025, but not because the wrapper became extremely lean. The cost line remained meaningful. The main difference is that the portfolio stopped dragging the entire statement down.

The second half of 2025 looked different, but it needs to be read correctly

This is one of the more interesting data points in the year's numbers. Based on the two-half summary, the first half of 2025 ended with a comprehensive loss of NIS 4.852 million, while the second half ended with comprehensive profit of NIS 811 thousand. That is a sharp swing within a single year.

But again, the source was not operational. The first half included a negative fair-value change of NIS 3.184 million, while the second half included a positive fair-value change of NIS 2.879 million. General and administrative expenses actually rose in the second half to NIS 2.053 million from NIS 1.618 million in the first half. So anyone claiming Unicorn "moved into profitability" is reading the second half too generously. What really happened is that the valuation line turned supportive in the second half.

That matters for the market as well. If another half-year brings renewed mark volatility, the accounting improvement can unwind quickly. So the real question is not whether Unicorn posted profit in one half. It is whether 2026 can bring additional external validation to the key portfolio marks.

Overhead declined, but it is still heavy relative to the model

General and administrative expenses fell to NIS 3.671 million. The breakdown sharpens the point: wages and related costs were NIS 1.372 million, management fees to the general partner dropped to NIS 819 thousand from NIS 1.249 million, professional consulting was NIS 921 thousand, and directors' fees were NIS 271 thousand. There is nothing obviously excessive here, but there is still a fairly fixed cost base sitting on top of an entity with no operating revenue.

That means that as long as Unicorn does not start realizing holdings or generating other sources of cash, even a more disciplined cost layer still consumes a meaningful part of the cash balance. The lower management-fee burden is good news, but it is not a model shift by itself.

The real competition is for deal quality, not for operating margin

The partnership itself defines its competitive field as technology incubators, other R&D partnerships, venture-capital funds, and angels. It also presents its management team, investment committee, and advisers as an advantage. That is a fair argument, but by the end of 2025 the public market still does not fully price that edge in. Why? Because an edge in venture-style investing is ultimately measured by the ability to source strong rounds, mark value early, and realize.

In 2025 there is plenty of investment activity, but there are still no realizations that prove the public wrapper knows how to turn portfolio selection into accessible public value. So the argument about having a professional team remains valid in the business description, but it is not yet proven on the screen.

Cash Flow, Debt And Capital Structure

This needs to be read through an all-in cash flexibility lens

In Unicorn's case, the right cash framework is all-in cash flexibility. The relevant question is not how much the portfolio "earned" on paper, but how much cash actually remained after all real uses of cash. In 2025 the picture was straightforward: cash started at NIS 13.342 million, the rights offering added NIS 7.314 million net, and against that the partnership used NIS 3.439 million in operating cash flow, NIS 3.290 million in investing cash flow, and lost NIS 425 thousand through FX effect. The year-end result was NIS 13.502 million.

This is the most important chart for understanding the risk wrapper. It shows that the cash balance was not built by realizations and not by operating activity. It was preserved by a fresh equity raise. Without the rights offering, year-end cash would have dropped to roughly NIS 6.2 million. So anyone reading the NIS 13.5 million cash line as a naturally accumulated cushion should remember that a large part of it came from public investors only a few months earlier.

There is no debt, but there is still capital dependence

On the debt side, the picture is very comfortable. At year-end, the partnership had no loans or external financing of any kind, and current liabilities were only NIS 725 thousand. This is not a story about covenants, refinancing, or bank pressure.

But the absence of debt does not eliminate funding risk. The partnership states explicitly that its activity involves high expenditure, a high degree of financial risk and uncertainty, and no certainty that future funding can be raised. That is a key point: Unicorn's risk is not default. It is the possibility that the capital market may not be willing to fund the next proof period on acceptable terms.

Even the investment pace requires a double read

There is another subtle but important point in the gap between portfolio investment and cash spent. The movement in financial assets shows NIS 3.629 million of additions in 2025, while the cash flow statement shows NIS 3.290 million of investment cash outflow. The difference, NIS 339 thousand, comes from the ActualSignal warrant exercise, which was recognized as an investment against payables and only paid in January 2026.

That is a good example of how Unicorn needs to be read: not only through the P&L, and not only through the investment line, but through the reconciliation between fair value, cash, and liabilities. Even here, the portfolio build was slightly larger than the cash-flow snapshot suggests.

Outlook And Forward View

Four points that need to hold into 2026:

• This is a proof year for NAV, not a harvest year. 2025 brought no meaningful realizations, and the partnership enters 2026 needing to prove that the accounting value can become accessible value.
• Strix is the central test. When one holding accounts for 43.5% of the portfolio, every change in how that holding is read changes the reading of the entire partnership.
• Flow-Lit offers external validation, but with clear execution conditions. Dor Chemicals is good news, but not fully locked money yet.
• The new SAFE layer broadens the portfolio, but it does not yet improve its public quality. A meaningful slice of value still rests on cost or very recent rounds rather than on realizations.

Strix is the key confidence test

It is hard to get around this. Strix alone is carried at NIS 13.286 million, versus NIS 7.812 million at the end of 2024. That is an annual uplift of NIS 5.474 million, and it is also the only holding for which the partnership attached a very material valuation discussion. The June 2025 valuation used a DCF model based on two scenarios: a high case at roughly USD 29 million and a low case at roughly USD 12 million, with equal weighting, for a weighted company value of roughly USD 20.4 million. The discount rate was 24%, and terminal growth was 3%.

The fact that the June work also served as the basis for the December 31, 2025 mark means the partnership did not identify a year-end indicator strong enough to require a new model. That could prove to be a strength if Strix keeps producing commercial or funding evidence. It could also prove to be a weakness if the coming year does not validate the valuation logic. Because of Strix's size, much of the 2026 debate around Unicorn will in practice be a debate around Strix.

Flow-Lit and LeO both matter, but in different ways

Flow-Lit stands at NIS 3.636 million, about 11.9% of the portfolio, and LeO at NIS 2.744 million, another 9.0%. These are already meaningful positions. Flow-Lit currently rests on a back-solve from the September 2025 Dor Chemicals round, while LeO rests on an updated year-end valuation based on multiples and OPM. These are different anchors: Flow-Lit benefits more from a concrete external event, while LeO benefits more from a modeled view of sales potential and peer valuation.

What they share is that both still need another stage of validation. In Flow-Lit's case, the last part of the USD 1 million depends on ATEX certification. In LeO's case, even after the additional February 2026 investment, what really matters is further commercialization proof or a new round that gives the market another external price point.

This shows why the market insists on caution. Five holdings account for more than 81% of the portfolio, and Strix alone is close to half of it. This is not a partnership spreading risk evenly across dozens of small and interchangeable positions. It depends on a handful of anchors.

The new SAFE bucket improves diversification, not necessarily value accessibility

If the portfolio is grouped by valuation anchor rather than by company name, another important picture emerges. The newer or cost-like positions, namely Supersi, Bioplasmar, VibeZ, San Brands, ActualSignal, Engini, and Inteil, together account for about NIS 9.6 million, roughly 31% of the portfolio. In most of these positions, the partnership explicitly says cost or the latest round remains the best estimate of fair value.

That matters for two reasons. First, it is a reasonable way to carry very young companies when there is still limited data. Second, it is also a clear limitation on NAV quality. As long as these positions do not move through another round, another external pricing event, or a realization, it is hard to expect the public market to give them full credit.

What has to happen in the next 2 to 4 quarters

For the Unicorn thesis to strengthen, what is needed is not another rights offering. Something else has to happen: external validation or realization. That could be another supportive Strix round, Flow-Lit turning the Dor Chemicals agreement into fully paid funding, commercialization progress in LeO, or any other event that moves value from the model layer toward a business or cash layer.

At the same time, wrapper discipline must hold. If general and administrative expenses start climbing again while the portfolio still does not return cash, then the cash balance will once again become the central point of dispute. That is why 2026 does not look like a breakout year. It looks like a proof year, with a double test: valuation quality and value accessibility.

Risks

Almost the entire portfolio is Level 3

This is the first and most obvious risk. As of December 31, 2025, essentially the full NIS 30.566 million portfolio is classified as Level 3, while the Level 1 layer, Cyberwan, is negligible. This is not just an accounting question. It is a confidence question. When the portfolio is almost entirely Level 3, a deep discount to NAV is not automatically a market mistake. It can also be the price of uncertainty.

Concentration is very high

The second risk is concentration. Strix, Flow-Lit, and LeO alone make up about 64% of the portfolio. The top five positions already account for more than 81%. That means that even though the portfolio contains a number of companies, the partnership's actual economics are not truly diversified. One cracked anchor can materially alter the read on the entire valuation case.

FX matters, and in 2025 it worked against the portfolio

The partnership explicitly states that the shekel appreciated by about 12.5% against the dollar in 2025, with another roughly 3.5% move through March 6, 2026. Because many portfolio investments are measured in US dollars, part of the fair-value movement came from FX translation. That matters because even if portfolio companies improve operationally, sharp shekel appreciation can still erode the accounting outcome in shekel terms.

Dilution is the practical risk, more than refinancing

There is no debt pressure here, but there is capital pressure. 2025 already showed that preserving cash required a rights offering. If 2026 still does not bring realizations or stronger external validation, the possibility that the public market will again be asked to finance the waiting period remains real. That is a much more practical risk than a solvency event.

Created value is not yet accessible value

At the start of 2024, the partnership adopted a profit-distribution policy under which realizations would be distributed, including both principal and gains, until cumulative distributions match total capital raised. That is interesting. But at the end of 2025 there is still no distributable surplus, and no meaningful realizations have started that mechanism. So even if some of the value carried inside the portfolio is real, it is still not automatically accessible to public unitholders.

Conclusions

Unicorn ends 2025 in a better place than it looked a year ago: less erosion, lower expenses, more time. But this is still not a fully proven story. What supports the thesis today is the absence of debt, a reasonable cash balance, and a portfolio that is no longer falling apart on paper. What still blocks a cleaner read is that almost all of the value above cash remains private, Level 3, and concentrated.

Current thesis in one line: Unicorn is no longer being tested on immediate survival, but on whether its NAV can become more than an accounting figure and start looking like value that can actually be realized.

What changed versus the 2024 read? Accounting losses stabilized, Strix gained far more weight and credibility, and wrapper costs came down after unitholders stopped the management-fee extension. The strongest counter-thesis says that this is already enough, because at a market cap of about NIS 20 million the public market is already giving almost no credit to anything beyond cash. That is a serious argument. But for it to win, 2026 will have to bring real proof events, not just another mark.

What could change the market's reading in the short to medium term? Another commercial update from Strix. Full milestone delivery at Flow-Lit. A round or commercialization event in LeO or one of the newer SAFE holdings. And above all, any sign that the partnership knows how not only to invest and mark value, but also to begin turning it into cash.

Why does this matter? Because in a partnership like this, portfolio quality is not measured only by each company's fair-value estimate, but by whether the public wrapper can turn private value into accessible public value. That is the core 2026 test.

What has to happen over the next 2 to 4 quarters for the thesis to strengthen? At least one major valuation anchor needs another external confirmation, wrapper costs need to remain disciplined, and cash cannot rely yet again mainly on a new capital raise. What would weaken the thesis? Another raise without validation, renewed erosion in the largest marks, or a continued situation in which cash keeps the partnership alive but does not bring it closer to realization.